Roivant Sciences (ROIV) EBT Margin (2020 - 2025)
Roivant Sciences (ROIV) reported EBT Margin of 14525.71% for Q4 2025, down 1192521.0% on a YoY basis from N/an in Q4 2024, and down 43.48% quarter-over-quarter from 10123.74% in Q3 2025.
Roivant Sciences (ROIV) EBT Margin (2020 - 2025) Analysis & Trends
Roivant Sciences has reported EBT Margin for 6 years, with the latest figure at 14525.71% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 1192521.0% year-over-year to 14525.71%; the trailing twelve-month figure through Dec 2025 stood at 6458.79% (down 1907860.0% YoY), and the FY2026 full-year result was 3203.12%, down 85710.0% from the prior year.
- EBT Margin for Q4 2025 stood at 14525.71%, down from 10123.74% in the prior quarter.
- The five-year high for EBT Margin was 33116.21% in Q4 2023, with the low at 14525.71% in Q4 2025.
- Historically, EBT Margin has averaged 2462.91% across 5 years, with a median of 2503.44% in 2022.
- Annual changes were most pronounced in 2023 — EBT Margin jumped 3535687 bps — and 2024, when it slumped 3571671 bps.
- Roivant Sciences' EBT Margin stood at 1257.33% in 2021, then slumped by 78 bps to 2240.66% in 2022, then surged by 1578 bps to 33116.21% in 2023, then tumbled by 108 bps to 2600.5% in 2024, then slumped by 459 bps to 14525.71% in 2025.
- The last three EBT Margin figures came in at 14525.71% (Q4 2025), 10123.74% (Q3 2025), and 12408.39% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14,525.71% |
| Sep 30, 2025 | -10,123.74% |
| Jun 30, 2025 | -12,408.39% |
| Dec 31, 2024 | -2,600.50% |
| Sep 30, 2024 | -5,014.15% |
| Jun 30, 2024 | -245.81% |
| Dec 31, 2023 | 33,116.21% |
| Sep 30, 2023 | -6,617.49% |
| Jun 30, 2023 | -1,508.01% |
| Dec 31, 2022 | -2,240.66% |
| Sep 30, 2022 | -2,503.44% |
| Jun 30, 2022 | -8,098.75% |
| Dec 31, 2021 | -1,257.33% |
| Sep 30, 2021 | -1,610.35% |
| Jun 30, 2021 | -1,305.56% |
| Dec 31, 2020 | -4,796.89% |
| Sep 30, 2020 | -3,989.95% |
| Jun 30, 2020 | -428.68% |